Most Popular
-
1
1 in 3 Koreans live alone, family types becoming diverse
-
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
3
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
4
K-pop singer lost consciousness after being hit by foul ball, cancels show
-
5
Contentious grain bill put directly to plenary meeting for vote
SK Holdings, the holding company of the nation’s third-largest conglomerate, held a board meeting last month to push for the market listing of its drug unit, according to industry sources Thursday.
With the board’s approval, SK Biopharmaceuticals is expected to apply for preliminary approval from the stock exchange soon, they added.
With the board’s approval, SK Biopharmaceuticals is expected to apply for preliminary approval from the stock exchange soon, they added.
In April, the drug unit named NH Investment and Securities to lead the initial public offering of the company and Korea Investment and Security as a joint manager.
The company is likely to make the market debut sometime after late November, local analysts say. It is waiting for the US Food and Drug Administration’s approval for sales of Cenobamate, an anti-epilepsy drug, in the US.
The estimated value of SK Biopharmaceuticals stands around 5 trillion won ($4.15 billion), according to local brokerage houses.
By Cho Chung-un (christory@heraldcorp.com)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
![[Today’s K-pop] Zico drops snippet of collaboration with Jennie](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/18/20240418050702_0.jpg&u=)